HANXBIO-B(03378.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 36.88 million, loss widened by 1.22% YoY
August 17, 2026, HANXBIO-B(03378.HK) released its Interim Report for the period ended December 31, 2026; Net Profit stood at loss of CNY 33.24 million, loss narrowed by 1.23% YoY; Profit Attributable to Shareholders stood at loss of CNY 36.88 million, loss widened by 1.22% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY 0.27.
By the close of trading on August 17, 2026, HANXBIO-B(03378) saw a loss of 3.62% in its share price, closing at HKD 29.28. The full-day turnover stood at HKD 655.2 thousand, with the latest market capitalization at HKD 3.93 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HANXBIO-B(03378.HK): Signs AI Drug R&D Cooperation Agreement with Frontier Interdisciplinary Research Center of Huazhong University of Science and Technology
- HANXBIO-B(03378.HK) Included in FTSE Global Micro Cap Index
- HANXBIO-B(03378.HK): Research Results of Four Innovative Drugs to Be Presented at AACR 2026
- Hanx Biopharmaceuticals(03378.HK): Enters AI Drug R&D Collaboration with TwinEdge Bioscience
- Hanx Biopharmaceuticals-B (03378.HK) Controlling Shareholders Voluntarily Extend Lock-Up by 12 Months
